tbuckley/cabot-search huggingface dataset:
Neuromuscular junctions are stable in patients with cancer cachexia
Authors: Ines Boehm, Janice Miller, Thomas M. Wishart, Stephen J. Wigmore, Richard J.E. Skipworth, Ross A. Jones, Thomas H. Gillingwater
Journal: Journal of Clinical Investigation (2019)

Cancer cachexia is a major cause of patient morbidity and mortality, with no efficacious treatment or management strategy. Despite cachexia sharing pathophysiological features with a number of neuromuscular wasting conditions, including age-related sarcopenia, the mechanisms underlying cachexia remain poorly understood. Studies of related conditions suggest that pathological targeting of the neuromuscular junction (NMJ) may play a key role in cachexia, but this has yet to be investigated in human patients. Here, high-resolution morphological analyses were undertaken on NMJs of rectus abdominis obtained from patients undergoing upper GI cancer surgery compared with controls (N = 30; n = 1,165 NMJs). Cancer patients included those with cachexia and weight-stable disease. Despite the low skeletal muscle index and significant muscle fiber atrophy (P < 0.0001) in patients with cachexia, NMJ morphology was fully conserved. No significant differences were observed in any of the pre- and postsynaptic variables measured. We conclude that NMJs remain structurally intact in rectus abdominis in both cancer and cachexia, suggesting that denervation of skeletal muscle is not a major driver of pathogenesis. The absence of NMJ pathology is in stark contrast to what is found in related conditions, such as age-related sarcopenia, and supports the hypothesis that intrinsic changes within skeletal muscle, independent of any changes in motor neurons, represent the primary locus of neuromuscular pathology in cancer cachexia.
Pre-arrest and intra-arrest prognostic factors associated with survival after in-hospital cardiac arrest: systematic review and meta-analysis
Authors: Shannon M Fernando, Alexandre Tran, Wei Cheng, Bram Rochwerg, Monica Taljaard, Christian Vaillancourt, Kathryn M Rowan, David A Harrison, Jerry P Nolan, Kwadwo Kyeremanteng, Daniel I McIsaac, Gordon H Guyatt, Jeffrey J Perry
Journal: BMJ (2019)

Abstract Objective To determine associations between important pre-arrest and intra-arrest prognostic factors and survival after in-hospital cardiac arrest. Design Systematic review and meta-analysis. Data sources Medline, PubMed, Embase, Scopus, Web of Science, and the Cochrane Database of Systematic Reviews from inception to 4 February 2019. Primary, unpublished data from the United Kingdom National Cardiac Arrest Audit database. Study selection criteria English language studies that investigated pre-arrest and intra-arrest prognostic factors and survival after in-hospital cardiac arrest. Data extraction PROGRESS (prognosis research strategy group) recommendations and the CHARMS (critical appraisal and data extraction for systematic reviews of prediction modelling studies) checklist were followed. Risk of bias was assessed by using the QUIPS tool (quality in prognosis studies). The primary analysis pooled associations only if they were adjusted for relevant confounders. The GRADE approach (grading of recommendations assessment, development, and evaluation) was used to rate certainty in the evidence. Results The primary analysis included 23 cohort studies. Of the pre-arrest factors, male sex (odds ratio 0.84, 95% confidence interval 0.73 to 0.95, moderate certainty), age 60 or older (0.50, 0.40 to 0.62, low certainty), active malignancy (0.57, 0.45 to 0.71, high certainty), and history of chronic kidney disease (0.56, 0.40 to 0.78, high certainty) were associated with reduced odds of survival after in-hospital cardiac arrest. Of the intra-arrest factors, witnessed arrest (2.71, 2.17 to 3.38, high certainty), monitored arrest (2.23, 1.41 to 3.52, high certainty), arrest during daytime hours (1.41, 1.20 to 1.66, high certainty), and initial shockable rhythm (5.28, 3.78 to 7.39, high certainty) were associated with increased odds of survival. Intubation during arrest (0.54, 0.42 to 0.70, moderate certainty) and duration of resuscitation of at least 15 minutes (0.12, 0.07 to 0.19, high certainty) were associated with reduced odds of survival. Conclusion Moderate to high certainty evidence was found for associations of pre-arrest and intra-arrest prognostic factors with survival after in-hospital cardiac arrest. Systematic review registration PROSPERO CRD42018104795
Rod-shape theranostic nanoparticles facilitate antiretroviral drug biodistribution and activity in human immunodeficiency virus susceptible cells and tissues
Authors: Bhavesh D. Kevadiya, Brendan Ottemann, Insiya Z. Mukadam, Laura Castellanos, Kristen Sikora, James R. Hilaire, Jatin Machhi, Jonathan Herskovitz, Dhruvkumar Soni, Mahmudul Hasan, Wenting Zhang, Sarella Anandakumar, Jered Garrison, JoEllyn McMillan, Benson Edagwa, R. Lee Mosley, Richard W. Vachet, Howard E. Gendelman
Journal: Theranostics (2019)

Human immunodeficiency virus theranostics facilitates the development of long acting (LA) antiretroviral drugs (ARVs) by defining drug-particle cell depots. Optimal drug formulations are made possible based on precise particle composition, structure, shape and size. Through the creation of rod-shaped particles of defined sizes reflective of native LA drugs, theranostic probes can be deployed to measure particle-cell and tissue biodistribution, antiretroviral activities and drug retention. Methods: Herein, we created multimodal rilpivirine (RPV) 177lutetium labeled bismuth sulfide nanorods (177LuBSNRs) then evaluated their structure, morphology, configuration, chemical composition, biological responses and adverse reactions. Particle biodistribution was analyzed by single photon emission computed tomography (SPECT/CT) and laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS) imaging. Results: Nanoformulated RPV and BSNRs-RPV particles showed comparable physicochemical and cell biological properties. Drug-particle pharmacokinetics (PK) and biodistribution in lymphoid tissue macrophages proved equivalent, one with the other. Rapid particle uptake and tissue distribution were observed, without adverse reactions, in primary blood-derived and tissue macrophages. The latter was seen within the marginal zones of spleen. Conclusions: These data, taken together, support the use of 177LuBSNRs as theranostic probes as a rapid assessment tool for PK LA ARV measurements.
The Combination of Bortezomib and NPI-0052 Exerts Anti-Tumor Activity in Waldenstrom Macroglobulinemia (WM).
Authors: Aldo Roccaro, Xavier Leleu, Antonio Sacco, Xiaoying Jia, Anne-Sophie Moreau, Hai Ngo, Abdelkareem Azab, Feda Azab, Evdoxia Hatjiharissi, Steven Treon, Teru Hideshima, Michael Palladino, Kenneth Anderson, Dharminder Chuahan, Irene Ghobrial
Journal: Blood (2007)
Bronchoscopic Evaluation of Pulmonary Complications in Patients Undergoing Reduced-Intensity Versus Full-Intensity Transplants.
Authors: Joseph Maslak, Daniel Kaul, James Connelly, Shin Mineishi, John E. Levine, Edward M. Peres, Carrie Kitko, Sung W. Choi, Yasser Khaled, Oleg I. Krijanovski, Stefanie Digiandomenico, Eric White, Thomas Braun, Pavan Reddy, Attaphol Pawarode, James L.M. Ferrara, Gregory A. Yanik
Journal: Blood (2008)
A Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase (RNR) in Combination with High-Dose Cytarabine (HiDAC) in Relapsed or Refractory Acute Myeloid Leukemia (AML): Pharmacokinetics (PK), Pharmacodynamic (PD) and Clinical Results.
Authors: Rebecca B. Klisovic, W. Blum, X. Wei, S. Liu, C. Kefauver, L. Huynh, J. A. Zwiebel, J. C. Byrd, M. R. Grever, G. Marcucci
Journal: Blood (2005)
Outcomes after Unrelated Cord Blood Transplantation in Children with Acute Lymphoblastic Leukemia. An Eurocord-Netcord Survey.
Authors: Vanderson Rocha, Gerard Michel, Nabil Kabbara, William Arcese, Juan Ortega, Anna Paola Iori, Luis Madero, Ka-Wah Chan, Franco Locatelli, Federico Garnier, Irina Ionescu, Peter Wernet, Eliane Gluckman
Journal: Blood (2005)
Mid‐regional pro‐adrenomedullin outperforms N‐terminal pro‐B‐type natriuretic peptide for the diagnosis of acute heart failure in the presence of atrial fibrillation
Authors: Win Sen Kuan, Irwani Ibrahim, Siew Pang Chan, Zisheng Li, Oi Wah Liew, Chris Frampton, Richard Troughton, Chris J. Pemberton, Jenny Pek Ching Chong, Li Ling Tan, Weiqin Lin, Shirley Beng Suat Ooi, A. Mark Richards
Journal: European Journal of Heart Failure (2019)
Effectiveness of Bosutinib in Chronic Myeloid Leukemia (CML) Who Have Received Multi Tyrosine Kinase Inhibitors (TKIs)
Authors: Jorge Cortes, Hagop M. Kantarjian, Guillaume Richard-Carpentier, Gautam M. Borthakur, Farhad Ravandi, Kiran Naqvi, Koji Sasaki, Tapan M. Kadia, Srdan Verstovsek, Guillermo Garcia-Manero, Courtney D. DiNardo, Naveen Pemmaraju, Naval G. Daver, Prithviraj Bose, Sherry A. Pierce, Samuel Dara, Elias Jabbour, Jorge E. Cortes
Journal: Blood (2019)
Expressing C/EBPα in prostate cancer cells stimulates cell proliferation and enhances anchorage-independent growth by abolishing the interaction of C/EBPα with CDK2 and 4 and E2F and activating AKT
Authors: Hong Yin, Mylinh Smith, Jonathan Glass
Journal: Cancer Research (2005)

4523  The expression of C/EBPα leads usually to the growth arrest of the cells and this gene has been postulated to be a tumor suppressor. However, both our data and others demonstrate that expression of C/EBPα in some cancer cells is not associated with growth arrest. We have previously demonstrated that C/EBPα expression is altered in prostate cancer compared to normal human prostate epithelium. However, it is not known whether the expression of C/EBPα is related either to prostate carcinogenesis or to prostate cancer progression. In this study, we further examine if the expression of C/EBPα affects the growth and colony formation of prostate cancer cells. A retrovirus expression system was used to induce a constant expression of C/EBPα in both PSA positive and negative prostate cancer cell lines, including LNCAP, PC3, and DU145. Cells with a high expression of C/EBPα showed distinct morphological phenotypes: LNCAP cells showed an epithelial-like appearance with little aggregation, while both PC3 and DU145 showed a fibroblast-like appearance and grew with some aggregation. Assaying anchorage-independent growth by colony formation in soft agar showed that colony number in C/EBPα expressing cells was 5-17 fold higher than that from non-expressing cells. In all three prostate cell lines, expression of C/EBPα significantly stimulated cell proliferation with the increase of proliferation being greatest in those lines with the greatest increase of C/EBPα. With high expression of C/EBPα the number of cells in S-phase of cell cycle increased by about 50% compared to cells transfected with viral vector alone. The more rapidly growing C/EBPα expressing cells exhibited increased expression of CDK2 and CDK4 and in these cells cell growth was not retarded by up-regulation of p21. In the C/EBPα expressing prostate cancer cells immunoprecipitation showed that the interaction of C/EBPα with CDK2, CDK4, and E2F was lost and it is these interactions that are supposed to be very important for C/EBPα-mediated growth arrest. Furthermore, the examination of the AKT cell survival pathway demonstrated that AKT was activated in all constructs of prostate cancer cell lines expressing C/EBPα. Compared with C/EBPα non-expressing cells, phosphorylated AKT was increased by 1.7 fold in PC3 cells and 60 fold in DU145 cells. We conclude that the constant expression of C/EBPα stimulates proliferation of prostate cancer cell lines and enhances anchorage-independent growth. This phenotype was associated with increased expression of cyclin-dependent kinases and abolishment of the interaction between C/EBPα and CDK2 and 4 as well as E2F. In these prostate cancer cells, multiple survival-related pathways, including the AKT pathway may be activated and contribute to blocking the C/EBPα-induced growth arrest which occurs in other cell types.
Abstract 15566: Validation of the Samsung S-Patch - A Novel Ambulatory ECG Monitoring Device
Authors: Selwyn P Wong, Kirsten Jacobsen, Nicole Signal, Celestina Chan, Jamie Voss
Journal: Circulation (2018)

Introduction: The Samsung S-Patch is a lightweight device (see Figure) enabling continuous (60 hours) ECG monitoring combined with a smartphone APP. The data is uploaded to a cloud-based system for...
Detection of exercise-induced silent ischemia and the sequence of ischemic events in coronary artery disease by radionuclide ambulatory ventricular function monitoring.
Authors: Ishtiaque H. Mohiuddin, Nagara Tamaki, Hirofumi Kambara, Ryuji Nohara, Shinji Ono, Kazumi Okuda, Chuichi Kawai, Junji Konishi, Shigetake Sasayama
Journal: Circulation (1994)

Twenty-seven patients with stable coronary artery disease were continuously monitored with an ambulatory radionuclide ventricular function monitor (VEST) during exercise to determine the prevalence of silent ischemia and the temporal sequence of events during ischemic episodes. Exercise-induced ejection fraction abnormality was considered a < 6% increase in the control value lasting for more than 60 sec. Patients performed exercise for 424 +/- 111 sec during VEST recording. Seventeen exercise-induced ejection fraction abnormalities were observed in 17 patients, of which eight (47%) were silent electrocardiographically and 12 (71%) were silent symptomatically. In all of the patients, exercise-induced ischemia occurred in a temporal sequence of ejection fraction abnormalities, ST depressions and then symptoms. In nine patients with ejection fraction and ST abnormalities, ejection fraction abnormalities occurred earlier (199 +/- 87 sec) than ST depressions (321 +/- 117 sec; p < 0.01). In five patients with symptoms (399 +/- 151 sec), the sequence was ejection fraction abnormalities (205 +/- 64 sec; P < 0.05) followed by ST depressions (266 +/- 101 sec; P < 0.05) and symptoms (399 +/- 151 sec; P < 0.01). After termination of exercise, ejection fraction (49 +/- 12 sec) recovered sooner than symptoms (102 +/- 27 sec; p < 0.01) or ST abnormalities (191 +/- 96 sec; p < 0.01). Thus, hemodynamic monitoring by VEST may be helpful in detecting ischemic episodes in coronary artery disease which remain electrocardiographically or symptomatically silent. Furthermore, exercise-stress induces a cascade of temporal changes in ischemic events which may be helpful in understanding the pathophysiology of ischemia.
Oral Melphalan, Prednisone and Thalidomide for Multiple Myeloma.
Authors: Antonio Palumbo, Sara Bringhen, Pellegrino Musto, Tommaso Caravita, Rosanna Capozzi, Vincenzo Callea, Clotilde Cangialosi, Marco Montanaro, Lucio Catalano, Mariella Grasso, Maria Concetta Petti, Manuela Merla, Lorenzo Falchi, Paola Omedè, Manuela Ceccarelli, Maria Teresa Ambrosini, Ilaria Avonto, Francesca Gay, Patrizia Falco, Mario Boccadoro
Journal: Blood (2005)
Blast karyotype at initial presentation affects outcome of autotransplants for acute myeloid leukemia in second remission
Authors: K. W. Song, P. N. Mollee, D. E. Hogge, V. Gupta, T. J. Nevill, S. H. Nantel, C. L. Toze, H. J. Sutherland, D. L. Forrest, J. D. Shepherd, J. C. Lavoie, M. Crump, A. Keating
Journal: Blood (2003)
NHS facing “critical” shortage of lung specialists this winter, professional body warns
Authors: Gareth Iacobucci
Journal: BMJ (2019)

A “critical” shortage of lung specialists may leave the NHS struggling to cope with a spike in hospital admissions related to complications of pneumonia and flu this winter, the British Thoracic Society (BTS) has warned.

At its winter meeting this week (taking place 4-6 December), the society presented results from a survey it conducted of almost 250 UK NHS respiratory specialists. Some 83% of respondents (199) thought respiratory healthcare staff shortages would impair the ability of the NHS to cope with the increase in lung disease hospital admissions this winter.

The society said the results were particularly concerning …
Gene Mutations as Predicitive Markers for Postremission Therapy in Younger Adults with Normal Karyotype AML.
Authors: Richard F. Schlenk, Andrea Corbacioglu, Jürgen Krauter, Lars Bullinger, Michael Morgan, Daniela Späth, Irina Schäfer, Stefan Frohling, Arnold Ganser, Hartmut Dohner, Konstanze Dohner
Journal: Blood (2006)
Reduced Intensity Allogeneic Transplantation Using BEAM-Alemtuzumab in Patients with Lymphoid Malignancy: Long Term Results and Impact of Intervention with DLI.
Authors: Emma P. Das-Gupta, Jennifer L. Byrne, Charles Craddock, Stephen Robinson, Stephen Devereux, Antonio Pagliuca, Grant McQuaker, Andrew P. Haynes, Ghulam Mufti, Nigel H. Russell
Journal: Blood (2005)
CD8+/TCR− Facilitating Cells Induce Generation of Regulatory T cells in Vivo: Chimeric Regulatory T Cells are Antigen-Specific and Enhance Engraftment of Allogeneic HSC in Non-Obese Diabetic (NOD) Mice.
Authors: Yiming Huang, Larry D Bozulic, Thomas Miller, Hong Xu, Lala-Rukh Hussain, Suzanne T. Ildstad
Journal: Blood (2008)
Quantitative Imaging Assessment for Clinical Trials in Oncology
Authors: Katherine E. Hersberger, Mishal Mendiratta-Lala, Rocky Fischer, Ravi K. Kaza, Isaac R. Francis, Mirabella S. Olszewski, John F. Harju, Wei Shi, Frank J. Manion, Mahmoud M. Al-Hawary, Vaibhav Sahai
Journal: Journal of the National Comprehensive Cancer Network (2019)

Background: Objective radiographic assessment is crucial for accurately evaluating therapeutic efficacy and patient outcomes in oncology clinical trials. Imaging assessment workflow can be complex; can vary with institution; may burden medical oncologists, who are often inadequately trained in radiology and response criteria; and can lead to high interobserver variability and investigator bias. This article reviews the development of a tumor response assessment core (TRAC) at a comprehensive cancer center with the goal of providing standardized, objective, unbiased tumor imaging assessments, and highlights the web-based platform and overall workflow. In addition, quantitative response assessments by the medical oncologists, radiologist, and TRAC are compared in a retrospective cohort of patients to determine concordance. Patients and Methods: The TRAC workflow includes an image analyst who pre-reviews scans before review with a board-certified radiologist and then manually uploads annotated data on the proprietary TRAC web portal. Patients previously enrolled in 10 lung cancer clinical trials between January 2005 and December 2015 were identified, and the prospectively collected quantitative response assessments by the medical oncologists were compared with retrospective analysis of the same dataset by a radiologist and TRAC. Results: This study enlisted 49 consecutive patients (53% female) with a median age of 60 years (range, 29–78 years); 2 patients did not meet study criteria and were excluded. A linearly weighted kappa test for concordance for TRAC versus radiologist was substantial at 0.65 (95% CI, 0.46–0.85; standard error [SE], 0.10). The kappa value was moderate at 0.42 (95% CI, 0.20–0.64; SE, 0.11) for TRAC versus oncologists and only fair at 0.34 (95% CI, 0.12–0.55; SE, 0.11) for oncologists versus radiologist. Conclusions: Medical oncologists burdened with the task of tumor measurements in patients on clinical trials may introduce significant variability and investigator bias, with the potential to affect therapeutic response and clinical trial outcomes. Institutional imaging cores may help bridge the gap by providing unbiased and reproducible measurements and enable a leaner workflow.
Generalized pustular psoriasis.
Journal: BMJ (1969)

Pustular psoriasis is a rare and extreme form of psoriasis characterized by the appearance of sterile pustules which can take many patterns. All the main pathological features of the disease are accentuated. Generalized pustular psoriasis is clinically heterogeneous in its age at onset, precipitants, severity, and natural history. Many overlapping clinical entities are recognized. There is a relationship between these entities and plaque psoriasis, as some individuals may have episodes of plaque psoriasis preceding or following the generalized pustular psoriasis, but in others generalized pustular psoriasis occurs as the sole phenotype without plaque psoriasis at any time.
Combination Therapy of Small Molecule Inhibitor PHA-739358 and Tyrosine Kinase Inhibitor Imatinib Yields Synergistic Antiproliferative Effects and Suppresses Emergence of Resistance of Chronic Myeloid Leukemia in Vitro
Authors: Stefan Balabanov, Artur Gontarewicz, Gunhild Keller, Jürgen Moll, Carsten Bokemeyer, Tessa L Holyoake, Tim H. Brummendorf
Journal: Blood (2008)
Genome-Wide Profiling of Endothelial Progenitor Cells in Multiple Myeloma: Disease-Relevant Pathways and Overlaps with Common Cancer Biomarkers
Authors: Marc J. Braunstein, Fabien Campagne, Piali Mukherjee, Daniel Ruben Carrasco, Kumar Sukhdeo, Alexei Protopopov, Kenneth C Anderson, Olcay Batuman
Journal: Blood (2008)
Association of miRNA expression and EGFR mutation status in lung adenocarcinomas.
Authors: Lixia Ju, Caicun Zhou
Journal: Journal of Clinical Oncology (2013)

e22044 Background: Epidermal growth factor receptor (EGFR) is frequently found to be activated by mutation or amplification in lung cancer. Though most patients with EGFR activating mutation response to EGFR-TKI, there are still about 30% patients showing no response. miRNA expression is deregulated in lung cancer, and miRNAs can regulate EGFR. So it is important to predict the candidate miRNAs that target EGFR and to investigate the availability of these candidate miRNA regulators in lung cancer. Methods: In this study, we investigated the miRNA expression in lung adenocarcinomas cell lines with mutated EGFR (H1650 and PC-9)and wild-type EGFR (H1299 and A549) using the Phalanx Human Whole Genome Microarray. Results: The expression of 1,732 miRNAs was evaluated and expression of individual miRNAs was validated by individual RT-PCR assays. Overall, miRNAs expression were different between these two groups. Hsa-let-7d-3p, hsa-miR-1307-5p, hsa-miR-141-3p, hsa-miR-200c-3p, hsa-miR-203, hsa-miR-3182, hsa-miR-4510, hsa-miR-934 were upregulated and hsa-miR-3196, hsa-miR-4450, hsa-miR-4649-5p were downregulated in the mutated EGFR group. Conclusions: It is suggested that there are different carcinogenic pathways for EGFR mutation tumors. Those miRNAs that associated EGFR mutation can be further explored for their application in target therapy and prognostics.
Results in Children and Adolescents Treated According to Study AML-BFM 98: Less Toxic Deaths in the Short-Cycle Arm Than in the 6-Week Consolidation Arm.
Authors: Ursula Creutzig, Reinhardt Dirk, Joerg Ritter, Norbert Graf, Johannes Herrmann, Thomas Klingebiel, Alfred Reiter, Helmut Gadner, Felix Niggli, Jan Stary, Martin Zimmermann
Journal: Blood (2005)
Abstract 13277: Characterization of Salivary Microbiota in Patients With Atherosclerosis and Its Potential as a Biomarker
Authors: Masaaki Hoshiga, Nahoko Kato-Kogoe, Shoichi Sakaguchi, Kuniyasu Kamiya, Michi Omori, Akemi Nitta, Yanhong Gu, Keisuke Fukui, Yuri Ito, Takashi Nakano, Junko Tamaki, Takaaki Ueno
Journal: Circulation (2019)

Introduction: It has been reported that oral bacteria is associated with atherosclerosis. However, the relationship between the oral microbiota and atherosclerosis remains unclear. We aimed to comp...
Cytokine Gene Polymorphisms and Outcome of Patients with Hodgkin Lymphoma: A Prospective Study of the Groupe D’Etude Des Lymphomes De L’Adulte
Authors: Herve Ghesquieres, Olivier Casasnovas, Marion Fournier, David Cox, Pauline Brice, Franck Morschhauser, Anne-Laure Borrel, Catherine Sebban, Vincent Ribrag, Corinne Haioun, Pierre Feugier, Herve Tilly, Christophe Ferme, Gilles Andre Salles
Journal: Blood (2008)
비알코올성 지방간 환자에서 대사증후군의 유병률
Authors: 문기원, 임정묵, 배상석, 이기만, 김석형, Chae， Hee-bok, Park， Seon Mee, Youn， Sei-jin
Journal: Clinical and Molecular Hepatology (2004)

목적: 비알코올성 지방간(nonalcoholic fatty liver disease, NAFLD)은 알코올 섭취 없이 간에 지방 변성, 염증세포 침윤, 섬유화 등이 발생하는 질환으로 약물이나 위장관 수술에 의해서 발생하기도 하지만 비만, 인슐린 저항성, 당뇨, 고지혈증과 같은 대사성 질환들에 자주 동반하여 나타난다. 대사증후군은 비만, 이상...